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Prevalence of Cardiovascular Disease Risk Factors in Childhood
Glomerular Diseases
Isa F. Ashoor, MD; Sarah A. Mansﬁeld, MS; Michelle M. O’Shaughnessy, MD; Rulan S. Parekh, MD; Jarcy Zee, PhD; Tetyana L. Vasylyeva,
MD; Amy J. Kogon, MD; Christine B. Sethna, MD; Dorey A. Glenn, MD; Aftab S. Chishti, MD; Donald J. Weaver, MD; Margaret E. Helmuth,
MA; Hilda E. Fernandez, MD; Michelle N. Rheault, MD; on behalf of the CureGN Consortium*
Background-—Cardiovascular disease is a major cause of morbidity and mortality in children with chronic kidney disease. We
sought to determine the prevalence of cardiovascular risk factors in children with glomerular disease and to describe current
practice patterns regarding risk factor identiﬁcation and management.
Methods and Results-—Seven-hundred sixty-one children aged 0 to 17 years with any of 4 biopsy-conﬁrmed primary
glomerular diseases (minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA
nephropathy/vasculitis) were enrolled at a median of 16 months from glomerular disease diagnosis in the multicenter
prospective Cure Glomerulonephropathy Network study. Prevalence of traditional (hypertension, hypercholesterolemia, and
obesity) and novel (proteinuria, prematurity, and passive smoke exposure) cardiovascular risk factors were determined at
enrollment and compared across glomerular disease subtypes. Frequency of screening for dyslipidemia and prescribing of lipid-
lowering or antihypertensive medications were compared across glomerular disease subtype, steroid exposure, and remission
status groups. Compared with the general population, all traditional risk factors were more frequent: among those screened,
21% had hypertension, 51% were overweight or obese, and 71% had dyslipidemia. Children who were not in remission at
enrollment were more likely to have hypertension and hypercholesterolemia. Fourteen percent of hypertensive children were
not receiving antihypertensives. Only 49% underwent screening for dyslipidemia and only 9% of those with conﬁrmed
dyslipidemia received lipid-lowering medications.
Conclusions-—Children with primary glomerular diseases exhibit a high frequency of modiﬁable cardiovascular risk factors,
particularly untreated dyslipidemia. Lipid panels should be routinely measured to better deﬁne the burden of dyslipidemia in this
population. Current approaches to screening for and treating cardiovascular risk factors are not uniform, highlighting a need for
evidence-based, disease-speciﬁc guidelines. ( J Am Heart Assoc. 2019;8:e012143. DOI: 10.1161/JAHA.119.012143.)
Key Words: cardiovascular disease risk factors • chronic kidney disease • high blood pressure • hypercholesterolemia
• hypertension • pediatrics
C ardiovascular disease (CVD) is a major cause of morbid-ity and mortality in children with chronic kidney disease
(CKD).1,2 In children on dialysis, cardiovascular mortality rates
are far higher than in the general pediatric population, and
CVD accounts for 33% to 36% of all deaths.3,4 As children with
CKD become young adults, CVD prevalence increases fur-
ther.5,6 Accordingly, The American Heart Association’s Expert
Panel on Population and Prevention Science and the Council for
Cardiovascular Disease in the Young included children with
CKD in the highest-risk group for CVD development.7
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ORIGINAL RESEARCH
Childhood glomerular diseases are most often primary
kidney disorders and less frequently secondary to systemic
diseases such as lupus or chronic infections such as hepatitis
B and C, and HIV infection. Primary glomerular diseases may
be caused by known genetic mutations affecting glomerular
basement membrane proteins, though the exact mechanism
for most cases remains incompletely understood and
attributed to immune-related mechanisms.8 Their incidence
ranges from 0.1 to 2 cases per 100 000 children per year.9
Despite their relative overall low frequency, they are a
common cause of childhood CKD, accounting for 29% of all
CKD cases in the 854 children enrolled in the CKiD (Chronic
Kidney Disease in Children) study,10 and 31% of all end-
stage renal disease cases in 11 186 index kidney transplant
recipients from the North American Pediatric Trials and
Collaborative Studies.11 Many glomerular diseases—including
minimal change disease (MCD), focal segmental glomeru-
losclerosis (FSGS), membranous nephropathy (MN) and, to a
lesser extent, IgA nephropathy/IgA vasculitis (IgAN/IgAV)—
are characterized by the presence of nephrotic syndrome.
Nephrotic syndrome is associated with hypertension,12 dys-
lipidemias,13 and often prolonged exposure to corticosteroids
leading to obesity and diabetes mellitus. However, the
prevalence of traditional and nontraditional CVD risk factors
in children with glomerular disease is not well described. Even
less is known about current practice patterns regarding CVD
risk factor evaluation and treatment in this population.
The Cure Glomerulonephropathy Network (CureGN) is a
prospective multicenter cohort study of children and adults
with glomerular disease funded by the National Institute of
Diabetes and Digestive and Kidney Diseases.14 We hypoth-
esized that children with glomerular disease, particularly
those with active nephrosis, have the highest prevalence of
CVD risk factors and are likely not receiving comprehensive
screening and treatment at a level commensurate with their
risk proﬁle. Therefore, we sought to describe the prevalence
of CVD risk factors in those children and to evaluate current
practice patterns regarding identiﬁcation and management of
their CVD risk proﬁle.
Methods
The supporting data are available at the National Institute of
Diabetes and Digestive and Kidney Diseases central data
repository.15
Study Sample
We performed a cross-sectional examination of all partici-
pants younger than 18 years old at the time of consent who
were enrolled in CureGN between December 2014 and
January 2018. CureGN enrolls participants from multiple
clinical sites in North America and Europe. Participants with a
diagnostic kidney biopsy within 5 years before enrollment
that meets pathologic criteria for MCD, FSGS, MN, or IgAN/
IgAV are eligible for inclusion. Those with end-stage renal
disease at the time of screening or any of the following at the
time of ﬁrst kidney biopsy are excluded: systemic lupus
erythematosus, HIV infection, diabetes mellitus, active hep-
atitis B/C, active malignancy, or prior solid organ/bone
marrow transplant. The study protocol was approved by the
Institutional Review Board at each participating center and all
participants provided written, informed consent or assent at
enrollment.
Data Collection
Demographic and clinical characteristics collected at study
enrollment included age, sex, race, ethnicity, glomerular
disease subtype, disease duration, medication use at or
before enrollment, and treatment responsiveness (ie, steroid
responsive, steroid-resistant, or multidrug resistant, as noted
in medical records by treating providers).
Other variables of interest included estimated glomerular
ﬁltration rate (eGFR), serum albumin, and urine protein-to-
creatinine ratio (UPCR). The central CureGN laboratory utilized
a Randox RX Daytona chemistry analyzer to measure serum
and urine creatinine using the Jaffe method, and urine protein
with a colorimetric method. When central measurements were
not available (74% serum creatinine, 80% UPCR), serum
creatinine and UPCR measurements performed in local
laboratories within 60 days before and after enrollment were
Clinical Perspective
What Is New?
• Children with primary glomerular diseases have a high
burden of cardiovascular disease risk factors relative to the
general pediatric population.
• The high burden of cardiovascular disease risk factors in
these children is seen irrespective of remission status or
steroid exposure duration.
• Screening and treatment practice patterns in these children,
particularly for dyslipidemia, are not uniform, and only 9% of
children with glomerular disease and dyslipidemia in this
cohort received lipid-lowering treatment.
What Are the Clinical Implications?
• Opportunities exist to target modiﬁable cardiovascular
disease risk factors (hypertension, dyslipidemia, and obe-
sity) in children with primary glomerular diseases.
• Consistent uniform screening strategies and treatment
guidelines, particularly for dyslipidemia, are urgently
needed.
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extracted from clinical records. Estimated GFR was calculated
using the modiﬁed Schwartz formula.16
CVD Risk Factors Deﬁnitions
We assessed the prevalence at enrollment of pre-existing CVD
or any of the following traditional (hypertension, obesity, and
dyslipidemia) or nontraditional (proteinuria, prematurity, and
second-hand smoke exposure) CVD risk factors. Three seated
casual blood pressure measurements were obtained after 5
minutes of rest using a calibrated site-dependent oscillometric
device at the enrollment visit. Consensus recommendations
for cuff size selection and patient preparation were followed at
all sites.17 Hypertension was deﬁned as a self-reported history
of hypertension. The second and third seated blood pressure
measurements were averaged and used to stratify blood
pressure level at enrollment. Patients were considered to have
a hypertensive-level casual blood pressure reading at enroll-
ment if the average blood pressure measurement exceeded
the 95th percentile for age, sex, and height.17 Participants
were considered to have a prehypertensive level casual blood
pressure at enrollment if the average blood pressure reading
was between the 90th and 95th percentile for age, sex, and
height. Weight and height were measured at enrollment visit
and body mass index (BMI) was calculated using the Centers
for Disease Control and Prevention BMI calculator. Weight was
classiﬁed using age- and sex-speciﬁc BMI percentiles from the
Centers for Disease Control and Prevention growth chart as
normal (BMI between the 5th percentile to less than the 85th
percentile), overweight (BMI from 85th to less than the 95th
percentile), or obese (BMI greater than or equal to the 95th
percentile).18 Lipid panels performed in local laboratories
were extracted from clinical records and were included if
performed before and up to 7 days following enrollment.
Fasting status information was not available. Dyslipidemia at
enrollment was deﬁned per the National Heart, Lung and
Blood Institute and the Kidney Disease: Improving Global
Outcomes clinical practice guidelines, and included a total
cholesterol ≥200 mg/dL, low-density lipoprotein ≥130 mg/
dL, high-density lipoprotein <40 mg/dL, or triglycerides
≥100 mg/dL (age 0–9 years) or ≥130 mg/dL (age 10–
18 years).19 Signiﬁcant proteinuria was deﬁned as UPCR >2
quantiﬁed by a 24-hour urine collection, a ﬁrst morning void,
or random spot urine. History of prematurity (birth before
37 weeks gestation), self-reported smoking or exposure to
second-hand smoke, and pre-existing CVD diagnoses includ-
ing coronary artery disease, heart failure, heart arrhythmia,
stroke, peripheral vascular disease, aortic aneurysm, and
valvular heart disease were obtained from participant inter-
views at enrollment visit. Participants were considered in
complete remission at enrollment if they had a UPCR <0.3 and
serum albumin >3 g/dL.
CVD Risk Factor Screening and Treatment
Practice Patterns
The following variables were extracted from patients’ local
medical records using a standardized data collection form:
lipid proﬁle measurement (yes/no), prescription of lipid-
lowering medication (yes/no), type of lipid-lowering medica-
tion, prescription of any antihypertensive medication, and
prescription of renin–angiotensin–aldosterone system (RAAS)
blockers speciﬁcally. Screening and treatment frequencies
were compared across the 4 glomerular disease types, and
across prespeciﬁed groups of interest (ie, participants with
versus without nephrotic range proteinuria, and those
prescribed versus not prescribed RAAS blockers).
Statistical Methods
Continuous variables were summarized as medians with
interquartile ranges (IQRs) and categorical variables as fre-
quencies. Demographic, clinical, medication, and practice
pattern data were compared across MCD, FSGS, MN, and
IgAN/IgAV groups, and practice pattern data were also
compared across proteinuria and RAAS blockade groups, using
a v2 or Fisher exact test for categorical variables and the
Kruskal–Wallis test for continuous variables. To compare the
prevalence of CVD risk factors between disease groups, using
IgAN/IgAV as the reference group, prevalence ratios were
estimated using a modiﬁed Poisson regression model with a
sandwich estimator.20 Modiﬁed Poisson rather than logistic
models were used because of our interest in prevalence ratios
rather than odds ratios, more robust standard error estimation,
and precision and consistency of effect estimates with
adjustment covariates.16,21 Models to estimate prevalence
ratios for hypertension, obesity, and hypercholesterolemia in
MCD, FSGS, and MN versus IgAN/IgAV participants were
adjusted for age, sex, race, and eGFR. We compared the
prevalence of CVD risk factors in the CureGN pediatric cohort
to prevalence reported in the US general pediatric population
using 1-sample binomial proportion tests.22–26 All analyses
were conducted using SAS software, Version 9.4 (2013; SAS
Institute Inc., Cary, NC).
Results
Cohort Description
A total of 761 children were included in this study: 283 (37%)
with MCD, 177 (23%) with FSGS, 36 (5%) with MN, and 265
(35%) with IgAN/IgAV (Table 1). The median age at disease
diagnosis was 9 years (IQR 5–13). Participants were enrolled
at a median of 16 months (IQR 5–37) since diagnosis and
11 months (IQR 3–29) since their kidney biopsy. Most
participants were white (71%), and the remaining were 18%
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black and 6% Asian. Hispanic or Latino ethnicity was reported
by 12%. Among white children, IgAN/IgAV predominated
(43%), 34% had MCD, and 19% had FSGS. Among black
children, MCD predominated (45%), 41% had FSGS, and only
8% had IgAN/IgAV. Children with MCD had longer disease
duration before enrollment, at 27 months versus 6 to
14 months in the other groups.
At enrollment, median eGFR was 103 mL/min per 1.73 m2
overall and exceeded 90 mL/min per 1.73 m2 in all disease
subgroups. Median serum albumin was normal at 3.8 g/dL
(IQR 3.0–4.2) and median UPCR was mildly elevated at
0.5 mg/mg (IQR 0.1–2.4). In 521 children with serum
albumin and UPCR measurements at enrollment, only 200
(38%) were in complete remission.
Immunosuppressive medication burden at enrollment was
high with 421 (55%) of children receiving either steroids or a
calcineurin inhibitor (Table 2). Steroid exposure duration
exceeded 6 months in 43% of participants who were ever
prescribed them (Table 3).
CVD Risk Factors
Traditional risk factors
Hypertension. Hypertension was frequently observed
(Table 4). Twenty-one percent of participants self-reported a
history of hypertension, and 22% had a hypertensive-level
casual clinic blood pressure reading at enrollment. Hyperten-
sive-level blood pressure readings were noted in 34% of those
Table 1. Pediatric CureGN Subjects
Median (IQR) or n (%)* Overall (n=761) MCD (n=283) FSGS (n=177) MN (n=36) IgAN (n=265)
Age at consent, y 11 (7–15) 8 (6–12) 13 (8–16) 15 (12–17) 12 (9–15)
Disease duration (mo since diagnosis) 16 (5–37) 27 (10–51) 14 (6–36) 6 (2–22) 11 (3–28)
Race‡
White 510 (71) 171 (65) 98 (58) 21 (64) 220 (87)
Black 132 (18) 59 (22) 54 (32) 9 (27) 10 (4)
Asian 43 (6) 21 (8) 6 (4) 1 (3) 15 (6)
Other 34 (5) 13 (5) 10 (6) 2 (6) 9 (4)
Hispanic/Latino† 94 (12) 35 (12) 20 (11) 8 (22) 31 (12)
Male 449 (59) 174 (61) 95 (54) 16 (44) 164 (62)
Disease classification
Steroid/multi-drug-resistant 134 (18) 56 (20) 59 (33) 8 (22) 11 (4)
Steroid sensitive 256 (34) 163 (58) 41 (23) 5 (14) 47 (18)
Untreated 101 (13) 22 (8) 28 (16) 5 (14) 46 (17)
Unknown/not applicable 270 (35) 42 (15) 49 (28) 18 (50) 161 (61)
eGFR, mL/min per 1.73 m²‡ 103 (86–124) 113 (94–134) 93 (69–114) 103 (89–129) 100 (86–119)
Serum albumin, g/dL§ 3.8 (3.0–4.2) 3.7 (2.8–4.2) 3.6 (2.6–4.2) 3.2 (2.2–4.0) 4.0 (3.6–4.2)
UPCR§ 0.5 (0.1–2.4) 0.2 (0.1–2.6) 1.2 (0.2–3.9) 2.0 (0.9–7.0) 0.4 (0.2–1.2)
Birth weight, kg§ 3.3 (3.0–3.7) 3.3 (2.9–3.7) 3.4 (2.9–3.7) 3.3 (3.0–3.5) 3.4 (3.1–3.7)
CureGN indicates Cure Glomerulonephropathy Network; EGFR, estimated glomerular ﬁltration rate; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; IQR, interquartile
range; MCD, minimal change disease; MN, membranous nephropathy; UPCR, urine protein-to-creatinine ratio (measured on 24–hour urine, ﬁrst morning void, or spot/random urine in
hierarchy as available).
*Percent reported among nonmissing observations.
†≤1% missing.
‡5% to 10% missing.
§10% to 20% missing.
Table 2. Immunosuppression at Enrollment
Overall (n=761) MCD (n=283) FSGS (n=177) MN (n=36) IgAN/IgAV (n=265)
Steroids, all 297 (39%) 138 (49%) 57 (32%) 11 (31%) 91 (35%)
CNI, all 232 (31%) 120 (43%) 84 (48%) 16 (44%) 12 (5%)
Steroids+CNI 108 (14%) 60 (21%) 34 (19%) 6 (17%) 8 (2%)
CNI indicates calcineurin inhibitor; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; IgAV, IgA vasculitis; MCD, minimal change disease; MN, membranous nephropathy.
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with a known diagnosis of hypertension and 19% of
normotensive children. After adjusting for between-group
differences in age and sex, a higher prevalence of hyperten-
sion or hypertensive-level blood pressure was evident among
participants with MN versus IgAN/IgAV; the association
persisted even after adjusting for race and eGFR (Table 5).
The prevalence of hypertension or hypertensive-level blood
pressure was similar among those with (38%) versus without
(42%) at least 6 months of steroid exposure (Table 6).
However, there was a signiﬁcant difference in the prevalence
Table 3. Steroid Exposure From Diagnosis to Enrollment
Overall (n=297) MCD (n=138) FSGS (n=57) MN (n=11) IgAN/IgAV (n=91)
<6 mo 133 (45%) 42 (30%) 28 (49%) 6 (55%) 57 (63%)
6–12 mo 45 (15%) 19 (14%) 11 (19%) 0 (0%) 15 (16%)
12–24 mo 43 (14%) 28 (20%) 3 (5%) 2 (18%) 10 (11%)
24+ mo 39 (13%) 31 (22%) 7 (12%) 0 (0%) 1 (1%)
Unknown 37 (12%) 18 (13%) 8 (14%) 3 (27%) 8 (9%)
FSGS indicates focal segmental glomerulosclerosis; IgAN, IgA nephropathy; IgAV, IgA vasculitis; MCD, minimal change disease; MN, membranous nephropathy.
Table 4. Cardiovascular Disease Burden in Pediatric CureGN Subjects at Enrollment
n (%)* Overall (n=761) MCD (n=283) FSGS (n=177) MN (n=36) IgAN/IgAV (n=265) P Value
Hypertension†,‡ 161 (21) 63 (22) 46 (26) 10 (28) 42 (16) 0.04
Blood pressure level at enrollment§
Normal 460 (64) 164 (61) 95 (58) 15 (46) 186 (74) 0.002
Prehypertensive 99 (14) 39 (15) 31 (19) 6 (18) 23 (9)
Hypertensive 160 (22) 66 (25) 38 (23) 12 (36) 44 (17)
Lipid screen collected 372 (49) 172 (61) 94 (53) 22 (61) 84 (32) <0.001
Dyslipidemia (any type), n/N (%) 265/372 (71) 132/172 (77) 67/94 (71) 20/22 (91) 46/84 (55) <0.001
Total cholesterol ≥200 mg/dL, n/N (%) 224/362 (62) 120/168 (71) 54/92 (59) 18/22 (82) 32/80 (40) <0.001
Triglycerides ≥100 mg/dL
(age 0–9) or ≥130 mg/dL (age 10–18), n/N (%)
158/257 (62) 82/114 (72) 41/63 (65) 13/19 (68) 22/61 (36) <0.001
HDL cholesterol <40 mg/dL, n/N (%) 44/198 (22) 14/90 (16) 13/51 (26) 4/13 (31) 13/44 (30) 0.17
LDL cholesterol ≥130 mg/dL, n/N (%) 104/178 (58) 58/81 (72) 20/45 (44) 9/13 (69) 17/39 (44) 0.004
Weight status at enrollment¶
Underweight 17 (2) 7 (3) 6 (4) 0 (0) 4 (2) 0.16
Normal 346 (46) 125 (45) 73 (43) 11 (31) 137 (52)
Overweight 143 (19) 61 (22) 28 (17) 9 (26) 45 (17)
Obese 239 (32) 86 (31) 62 (37) 15 (43) 76 (29)
Exposure to firsthand smoke 12 (2) 0 (0) 4 (2) 1 (3) 7 (3) 0.01
Exposure to secondhand smoke¶ 176 (24) 73 (26) 35 (21) 11 (32) 57 (23) 0.39
Prematurity (<37 wks)¶ 87 (12) 30 (11) 22 (13) 3 (9) 32 (13) 0.84
Pre-existing CVD‡,# 14 (2) 6 (2) 4 (2) 1 (3) 3 (1) 0.58
CureGN indicates Cure Glomerulonephropathy Network; CVD, cardiovascular disease; FSGS, focal segmental glomerulosclerosis; HDL, high-density lipoproteins; IgAN, IgA nephropathy;
IgAV, IgA vasculitis; LDL, low-density lipoprotein; MCD, minimal change disease; MN, membranous nephropathy.
*Percent reported among nonmissing observations.
†Self-reported history of hypertension.
‡<1% missing.
§5% to 10% missing.
¶1% to 5% missing.
#Heart arrhythmia (n=8), valvular heart disease (n=4), peripheral vascular disease (n=2), aortic aneurysm (n=1), coronary artery disease (n=1), heart failure (n=1), stroke (n=1).
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of hypertension or hypertensive-level blood pressure among
those who were (29%) versus were not (44%) in complete
remission at enrollment, P<0.001 (Table 7).
Twenty-six percent of participants with hypertension or
hypertensive-level blood pressure were not receiving any
antihypertensive medication at enrollment, and only 68% were
treated with RAAS-blocking medications (Table 8). RAAS
blockers were prescribed most frequently for hypertensive
participants with FSGS at 84%. The proportion of hypertensive
participants receiving treatment with any antihypertensive
agent or with a RAAS blocker speciﬁcally was similar
regardless of the presence or absence of nephrotic-range
proteinuria (89% and 79% in those with UPCR >2 versus 85%
and 79% in those with UPCR≤2, P=0.5 and P=1.0,
respectively).
Dyslipidemia. Only 49% of our study population had
evidence of lipid screening. Among those with lipids mea-
sured, 265 (71%) had dyslipidemia of any type, and 224 (62%)
had hypercholesterolemia. Hypercholesterolemia was most
Table 5. Prevalence Ratios for Cardiovascular Risk Factors, by Disease
Model 1: Unadjusted Model 2: Adjusted for Age, Sex Model 3: Model 2+Race Model 4: Model 3+Enrollment eGFR
Hypertension or hypertensive-level blood pressure*
MCD 1.4 (1.1–1.8) 1.3 (1.0–1.7) 1.2 (1.0–1.6) 1.3 (1.0–1.7)
FSGS 1.5 (1.1–1.9) 1.5 (1.1–1.9) 1.3 (1.0–1.7) 1.3 (1.0–1.8)
MN 2.0 (1.4–2.8) 2.1 (1.4–3.0) 1.9 (1.3–2.8) 1.9 (1.3–2.8)
IgAN/IgAV Ref. Ref. Ref. Ref.
Hypercholesterolemia
MCD 1.8 (1.3–2.4) 1.7 (1.2–2.2) 1.6 (1.2–2.1) 1.6 (1.2–2.1)
FSGS 1.5 (1.1–2.0) 1.4 (1.0–1.9) 1.3 (1.0–1.8) 1.4 (1.0–1.9)
MN 2.0 (1.5–2.9) 2.1 (1.5–2.9) 2.1 (1.5–2.9) 2.1 (1.5–2.9)
IgAN/IgAV Ref. Ref. Ref. Ref.
Obesity
MCD 1.1 (0.8–1.4) 1.0 (0.8–1.3) 1.0 (0.7–1.3) 0.9 (0.7–1.3)
FSGS 1.3 (1.0–1.7) 1.3 (1.0–1.7) 1.2 (0.9–1.6) 1.1 (0.8–1.5)
MN 1.5 (1.0–2.3) 1.6 (1.0–2.4) 1.5 (1.0–2.4) 1.4 (0.9–2.2)
IgAN/IgAV Ref. Ref. Ref. Ref.
eGFR indicates estimated glomerular ﬁltration rate; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; IgAV, IgA vasculitis; MCD, minimal change disease; MN,
membranous nephropathy; ref, reference.
*Self-reported history or enrollment systolic and/or diastolic blood pressure >95th percentile.
Table 6. Cardiovascular Risk Factors, by Steroids Exposure
at Enrollment
Steroid Exposure from Diagnosis to Enrollment
<6 Months (n=133) 6+ Months (n=127)
Hypertension or
hypertensive-level
blood pressure*
56 (42%) 48 (38%)
Hypercholesterolemia
TC measured 56 (42%) 76 (60%)
TC >200 42/56 (75%) 53/76 (70%)
Obesity 47 (35%) 44 (35%)
TC indicates total cholesterol.
*Self-reported history or enrollment systolic and/or diastolic blood pressure >95th
percentile.
Table 7. Cardiovascular Risk Factors, by Remission Status at
Enrollment
In Remission at Enrollment*
Yes (n=200) No (n=321)
Hypertension or
hypertensive-level
blood pressure†
58 (29%) 141 (44%)
Hypercholesterolemia
TC measured 110 (55%) 160 (50%)
TC >200 47/110 (43%) 115/160 (72%)
Obesity 57 (29%) 111 (35%)
TC indicates total cholesterol.
*Remission=serum albumin >3 g/dL and urine protein-to-creatinine ratio <0.3.
†
Self-reported history or enrollment systolic and/or diastolic blood pressure >95th
percentile.
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frequent in MN (82%) followed by MCD (71%), and least
frequent in IgAN/IgAV (40%) (Table 4). Hypercholesterolemia
was frequently observed regardless of steroid exposure
duration (Table 6). Among screened participants in complete
remission, 43% had hypercholesterolemia compared with 72%
of those not in remission (P<0.001) (Table 7).
Only 25 children with dyslipidemia (9%) were prescribed a
lipid-lowering medication, which included statins, ﬁsh oil, or
bile acid sequestrants. Forty-three of the 78 children treated
with lipid-lowering agents lacked a lipid proﬁle measurement,
of whom 33 received ﬁsh oil. Normal lipid proﬁles were noted in
10 children treated for dyslipidemia. The frequency of lipid-
lowering medications differed across glomerular disease
causes (Table 8). Overall, participants with MCD were least
likely to receive lipid-lowering treatment, whereas those with
MN or IgAN/IgAV were more likely. The proportion of those
treated with lipid-lowering medications was also almost 2 times
higher in participants with nephrotic-range proteinuria (UPCR
>2) compared with those without (16% versus 9%, P=0.02).
Finally, lipid-lowering medication use was almost twice as high
in RAAS blocker users at 13% versus 6% in nonusers.
Obesity. Based on BMI percentile at study enrollment, 51%
were either overweight (19%) or obese (32%); only 2% and 5%
of overweight and obese participants, respectively, had
moderate or severe edema noted on their enrollment visit
physical examination with 78% and 79%, respectively, having
no edema at all. Relative to participants with IgAN/IgAV, the
prevalence ratio of obesity was slightly higher among
patients with MN, although CIs were wide (Table 5). There
was no difference in the proportion of obese participants in
relation to steroid exposure duration (Table 6). The propor-
tion of obese participants was lower in those in complete
remission, though not signiﬁcantly different from those who
were not (Table 7).
Nontraditional risk factors
Proteinuria. Overall, the median UPCR was subnephrotic at
enrollment (Table 1). The highest median UPCR was observed
in the MN group at 2.0 (IQR 0.9–7.0). RAAS blockers were
frequently prescribed (Table 8) with use in 58% of all children
including 58% of those with nephrotic range proteinuria (UPCR
>2), 71% of those with a UPCR of 0.3≤ and ≤2, and 52% in
those with UPCR <0.3. The highest proportion of participants
on RAAS blockers were those with FSGS (73%), and the lowest
in participants with MCD (42%). RAAS blocker use was more
frequent in children with steroid/multi-drug-resistant
glomerular disease compared with steroid-sensitive disease
(67% versus 48%), P<0.001.
Other factors. Exposure to ﬁrsthand smoke was limited to
12 participants, while 24% reported exposure to secondhand
smoke at home. Twelve percent were born prematurely.
Comparison to the general pediatric population
Except for prematurity, all risk factors were more frequent
among children with glomerular disease (Figure).
Discussion
Our study examines the cardiovascular risk proﬁle in the
pediatric CureGN cohort, which represents the largest cohort
of children with 4 common and biopsy-conﬁrmed glomerular
diseases assembled to address these questions, and provides
a contemporary description of practitioners’ practice patterns
in screening and treatment of CVD risk factors in this high-risk
Table 8. Screening and Treatment Practice Patterns for CVD Disease Risk Factors in Pediatric CureGN Subjects
n/N (%) Overall (n=761) MCD (n=283) FSGS (n=177) MN (n=36) IgAN/IgAV (n=265) P value
Patients with any hypertension*, whole cohort† 268/761 (35) 108/283 (38) 70/177 (40) 19/36 (53) 71/265 (27) 0.001
Number on any antihypertensive medication 197/268 (74) 74/108 (69) 59/70 (84) 14/19 (74) 50/71 (70) 0.12
Number on RAAS blocker 181/268 (68) 68/108 (63) 54/70 (77) 14/19 (74) 45/71 (63) 0.18
Patients on RAAS blocker, whole cohort† 444/761 (58) 120/283 (42) 130/177 (73) 24/36 (67) 170/265 (64) <0.001
Among those with UPCR >2 98/168 (58) 30/62 (48) 35/51 (69) 9/15 (60) 24/40 (60) 0.19
Patients prescribed lipid- lowering medication, whole cohort† 78/761 (10) 9/283 (3) 17/177 (10) 6/36 (17) 46/265 (17) <0.001
Among patients with lipid profile measured 35/372 (9) 5/172 (3) 13/94 (14) 6/22 (27) 11/84 (13) <0.001
Among patients with TC >200 mg/dL‡ 19/224 (9) 4/120 (3) 8/54 (15) 6/18 (33) 1/32 (3) <0.001
Among patients with dyslipidemia of any type 25/265 (9) 4/132 (3) 9/67 (13) 6/20 (30) 6/46 (13) <0.001
CureGN indicates Cure Glomerulonephropathy Network; CVD, cardiovascular disease; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; IgAV, IgA vasculitis; MCD, minimal
change disease; MN, membranous nephropathy; RAAS blocker, renin-angiotensin-aldosterone system blocker; TC, total cholesterol; UPCR, urine protein-to-creatinine ratio.
*Self-reported history or enrollment systolic and/or diastolic blood pressure >95th percentile.
†<1% missing.
‡Total cholesterol: MCD missing 41%, FSGS missing 48%, MN missing 39%, IgAN missing 70%.
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pediatric population in North America and Europe. As
hypothesized, our ﬁndings conﬁrm the high prevalence of
CVD risk factors in children with glomerular disease and
highlight potential areas for improvement in screening and
treatment of these risk factors. Despite the relatively mild
degree of CKD at enrollment (median eGFR exceeded 90 mL/
min per 1.73 m2 in all subgroups), hypertension was reported
by almost one fourth of patients, with a similar percentage
exhibiting a hypertensive-level blood pressure reading at their
initial visit. Similarly, more than half were either overweight or
obese, and in those who underwent lipid screening more than
two thirds had dyslipidemia. Another concerning ﬁnding is the
presence of these risk factors at a high prevalence regardless
of cumulative steroid exposure duration, and even in the
minority (38%) that were in complete remission at the time of
enrollment.
In comparison, the prevalence of systolic hypertension,
overweight/obesity, and dyslipidemia in the CKiD cohort was
14%, 24%, and 45%, respectively.27,28 The Cardiovascular
Comorbidity in Children with Chronic Kidney Disease (4C)
study reported that 26% of patients had uncontrolled
hypertension and 23% were overweight/obese.29 The NEP-
TUNE (Nephrotic Syndrome Study Network) study reported
that 42% and 57% patients had uncontrolled hypertension and
were overweight/obese, respectively.30 In CureGN, the
prevalence of hypertensive-level blood pressure at enrollment
of 22% is lower than the similar NEPTUNE cohort, which may
reﬂect a longer disease duration before the enrollment visit in
CureGN, offering an opportunity to achieve better blood
pressure control. We also report a higher prevalence of
overweight/obesity (51%) compared with CKiD (24%) or 4C
(23%), but comparable to the NEPTUNE cohort (57%). This
may be secondary to side effects of steroids or other
medications used to treat glomerular diseases, or elevated
weights because of edema in participants with nephrotic
syndrome, although we noted that moderate or severe
edema was present in only 5% of obese participants. For
children in the CureGN cohort who underwent lipid screen-
ing, the prevalence of dyslipidemia (71%) is higher than
previously reported in the CKiD study (45%). This may be
because of increased prevalence of dyslipidemia in children
with proteinuria or nephrotic syndrome related to change in
cholesterol metabolism, or because of a selected higher-risk
population receiving cholesterol screening in the CureGN
cohort. This is suggested by the higher prevalence ratios for
hypercholesterolemia and to a lesser extent hypertension in
children with MCD and MN relative to their counterparts with
IgAN/IgAV (Table 5). The former 2 conditions almost univer-
sally present with nephrotic syndrome and nephrotic-range
proteinuria, whereas the latter typically presents with
subnephrotic range proteinuria, and hematuria.8 Most con-
cerning, though, was the much higher prevalence of
traditional CVD risk factors compared with the general
pediatric population (Figure), as these potentially modiﬁable
risk factors are present in children early in their glomerular
disease course (median of 16 months since diagnosis),
placing them at increased risk of developing overt cardio-
vascular disease as they age.
Figure. Cardiovascular risk disease burden in CureGN patients vs general pediatric population. *2004
National preterm birthrate, median year of birth for CureGN patients.22–26 CureGN indicates Cure
Glomerulonephropathy Network.
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Our study highlights deﬁciencies and opportunities for
improvement in screening and treatment patterns. It is
apparent from our ﬁndings that screening for and treatment
of CVD risk factors is not universal. For example, if patients
were hypertensive, antihypertensives were prescribed in only
86% of patients. Similarly, RAAS blockers were prescribed in
only 58% of those with nephrotic-range proteinuria. Perhaps
the most notable ﬁnding is the lack of universal screening for
lipid abnormalities in children who would be considered at high
risk for dyslipidemia because of their underlying disease. Our
study also highlights a reluctance to prescribe lipid-lowering
medications, likely reﬂecting a lack of consensus regarding the
relative risks and beneﬁts of pharmacologic treatment of
dyslipidemia in children in general.31,32 We hypothesize that
the remitting–relapsing nature of childhood nephrotic syn-
drome may dissuade providers from aggressively screening for
and treating CVD risk factors because of the perceived
“transient” risk; however, only 38% of patients were in
complete remission at a median of 12 months following
diagnosis, and the prevalence of hypertension, obesity, and
hypercholesterolemia remained high even among children who
were in remission. Therapeutic nihilism might therefore result
in a missed opportunity to improve the long-term cardiovas-
cular risk proﬁle.
This study has several limitations. We were limited to a
cross-sectional analysis of the enrollment visit dataset for the
purposes of this report and did not have access to longitudinal
follow-up data, which are currently being accrued. The focus
of future analyses will be on longitudinal data examining the
relationship between baseline cardiovascular risk factors and
future events including cardiovascular events, hospitaliza-
tions, and progression to end-stage renal disease in both
children and adults. Despite this limitation, the exclusive
focus on children with 4 common biopsy-conﬁrmed glomeru-
lar diseases is a major strength of our report. Previous similar
cohort studies (CKiD, 4C Study) had limited numbers of
children with glomerular disease (22% and 9%, respectively)
and the NEPTUNE cohort had only 147 children with nephrotic
syndrome enrolled at the time of kidney biopsy.28–30 Despite
the prospective design of CureGN, some clinical data for this
cohort were collected retrospectively. Therefore, some data
may be missing because of transition of care or other lapses,
which might account for the low prevalence of lipid screening.
However, the higher frequency of complete data available for
other parameters such as eGFR, serum albumin, and UPCR
suggests that the low prevalence of lipid screening is
reﬂective of a clinical practice gap. For the available lipid
measurements, we were not able to determine the fasting or
postprandial nature of the collections. While this may interfere
with the accuracy of triglyceride measurements, the high
prevalence of hypercholesterolemia (62%) should not be
signiﬁcantly affected. Centralized laboratory measurements
for serum creatinine and UPCR were completed for approxi-
mately one quarter of participants by the time of reporting;
therefore, we relied on local laboratory data extracted from
clinical records for most participants, which may introduce
technique-based variability. The lack of temporal relationship of
certain factors, such as availability of UPCR at time of lipid
measurements, limits the ability to accurately investigate risk
factor interactions. Additionally, biomarkers related to glucose
metabolism such as glycated hemoglobin, which is very
relevant for this population given the high prevalence of
overweight and obesity as well as the potential diabetogenic
side effects of the medications commonly used to treat
nephrotic syndrome, are not collected or centrally measured
as part of the current study protocol. It is an important clinical
question that could be the focus of an ancillary study proposal
by our group or any interested member of the larger scientiﬁc
community. Finally, the designation of hypertensive and
prehypertensive-level enrollment blood pressure readings fol-
lowed the normative data introduced in the Fourth Report, as it
was the reference blood pressure practice guideline at the time
of the patients’ diagnosis and enrollment. The 2017 American
Academy of Pediatrics Clinical Practice Guideline for screening
and management of high blood pressure in children and
adolescents has since replaced the Fourth Report.33 The
exclusion of obese children from the reference group utilized to
determine blood pressure percentile cutoffs in the 2017
guideline33 essentially leads to more strict cutoffs, which
would further increase the prevalence of hypertensive-level
readings in our cohort had they been analyzed utilizing the new
guideline cutoffs.
In conclusion, there is a high prevalence of potentially
modiﬁable CVD risk factors in a large cohort of children with
primary glomerular diseases. There appear to be ample
opportunities for process improvement and targeted efforts to
improve identiﬁcation and treatment of those risk factors in
high-risk patient populations, particularly children with clini-
cally complicated nephrotic syndrome course. Future efforts
need to better align clinical practice with existing treatment
guidelines, facilitate the conduct of interventional studies
aiming to determine best practice, and ultimately the
development of evidence-based, disease-speciﬁc clinical
practice guidelines.
Appendix
The CureGN Consortium members (from within the 4
Participating Clinical Center networks and the Data Coordi-
nating Center; authors above have been removed from this
list). CureGN Principal Investigators are noted (*).
Columbia University: Wooin Ahn, Columbia; G.B. Appel,
Columbia; R. Babayev, Columbia; I. Batal, Columbia; A.S.
Bomback, Columbia; E. Brown, Columbia; E.S. Campenot,
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Columbia; P. Canetta, Columbia; B. Chan, Columbia; D.
Chatterjee, Columbia; V.D. D’Agati, Columbia; E. Delbarba,
Columbia; H. Fernandez, Columbia; B. Foroncewicz, University
of Warsaw, Poland; A.G. Gharavi, Columbia*; G. M. Ghiggeri,
Gaslini Children’s Hospital, Italy; W.H. Hines, Columbia; N.G.
Jain, Columbia; B.H. Kil, Columbia; K. Kiryluk, Columbia; W.L.
Lau, Columbia; F. Lin, Columbia; F. Lugani, Gaslini Children’s
Hospital, Italy; M. Marasa, Columbia; G. Markowitz, Columbia;
S. Mohan, Columbia; X. Mu, Columbia; K. Mucha, University of
Warsaw, Poland; T.L. Nickolas, Columbia; S. Piva, Columbia; J.
Radhakrishnan, Columbia; M.K. Rao, Columbia; S. Sanna-
Cherchi, Columbia; D. Santoriello, Columbia; M.B. Stokes,
Columbia; N. Yu, Columbia; A.M. Valeri, Columbia; R. Zviti,
Columbia.
Midwest Pediatric Nephrology Consortium (MWPNC): Larry
A. Greenbaum*, Emory University; W.E. Smoyer*, Nationwide
Children’s; Amira Al-Uzri Oregon Health & Science University;
I. Ashoor, Louisiana State University Health Sciences Center;
D. Aviles, Louisiana State University Health Sciences Center;
R. Baracco, Children’s Hospital of Michigan; J. Barcia,
University of Virginia; S. Bartosh, University of Wisconsin; C.
Belsha, Saint Louis University/Cardinal Glennon; C. Bowers,
Nationwide Children’s Hospital; M.C. Braun, Baylor College of
Medicine/Texas Children’s Hospital; A. Chishti, University of
Kentucky; D. Claes, Cincinnati Children’s Hospital; C. Cramer,
Mayo Clinic; K. Davis, Washington University in St. Louis; E.
Erkan, Cincinnati Children’s Hospital Medical Center; D. Feig,
University of Alabama, Birmingham; M. Freundlich, University
of Miami/Holtz Children’s Hospital; R. Gbadegesin, Duke
University Medical Center; M. Hanna, Children’s Colorado/
University of Colorado; G. Hidalgo, East Carolina University;
T.E. Hunley, Monroe Carell Jr Children’s Hospital at Vanderbilt
University Medical Center; A. Jain, Children’s Hospital of
Michigan; M. Khalid, JW Riley Hospital for Children, Indiana
University School of Medicine, Indianapolis, IN; M. Kallash,
Nationwide Children’s Hospital; J.C. Lane, Feinberg School of
Medicine, Northwestern University; J. Mahan, Nationwide
Children’s; N. Mathews, University of Oklahoma Health
Sciences Center; C. Nester, University of Iowa Stead Family
Children’s Hospital; C. Pan, Medical College of Wisconsin; L.
Patterson, Children’s National Health System; H. Patel,
Nationwide Children’s Hospital; A. Revell, Nationwide Chil-
dren’s Hospital; M.N. Rheault, University of Minnesota Masonic
Children’s Hospital; C. Silva, Connecticut Children’s Medical
Center; R. Sreedharan, Medical College of Wisconsin; T.
Srivastava, Children’s Mercy Hospital; J. Steinke, Helen DeVos
Children’s Hospital; K. Twombley, Medical University of South
Carolina; S.E. Wenderfer, Baylor College of Medicine/Texas
Children’s Hospital; T.L. Vasylyeva, Texas Tech University
Health Sciences Center; D.J. Weaver, Levine Children’s Hospital
at Carolinas Medical Center; C.S. Wong, University of New
Mexico Health Sciences Center.
The University of North Carolina (UNC): Anand Achanti,
Medical University of South Carolina (MUSC); S. Almaani, The
Ohio State University (OSU); I. Ayoub, OSU; M. Budisavljevic,
MUSC; V. Derebail, UNC; R. Falk, UNC*; H. Fatima, The
University of Alabama at Birmingham (UAB); A. Fogo,
Vanderbilt; T. Gehr, Virginia Commonwealth University
(VCU); K. Gibson, UNC; D. Glenn, UNC; R. Harris, Vanderbilt;
S. Hogan, UNC Koyal Jain, UNC; J. Charles Jennette, UNC; B.
Julian, UAB; J. Kidd, VCU; L.-P. Laurin, Ho^pital Maisonneuve-
Rosemont (HMR) Montreal, H. Davis Massey, VCU; A. Mottl,
UNC; P. Nachman, UNC; T. Nadasdy, MUSC; J. Novak, UAB; S.
Parikh, OSU; V. Pichette, HMR Montreal; T.B. Powell,
Columbia Nephrology Associates; M. Renfrow, UAB; D. Rizk,
UNC; B. Rovin, OSU; V. Royal, HMR Montreal; M. Saha, UNC;
N. Sanghani, Vanderbilt, S. Self, MUSC.
University of Pennsylvania (UPENN): Sharon Adler, Los
Angeles Biomedical Research Institute at Harbor, University of
California Los Angeles (UCLA); C. Alpers, University of
Washington; R.B. Matar, Cleveland Clinic; E. Brown, University
of Texas (UT) Southwestern Medical Center; D. Cattran,
University of Toronto; M. Choi, Johns Hopkins; K.M. Dell, Case
Western/Cleveland Clinic; R. Dukkipati, Los Angeles Biomed-
ical Research Institute at Harbor UCLA; F.C. Fervenza, Mayo
Clinic; A. Fornoni, University of Miami; C. Gadegbeku, Temple
University; P. Gipson, University of Michigan; L. Hasely,
University of Washington; S. Hingorani, Seattle Children’s
Hospital; M. Hladunewich, University of Toronto/Sunnybrook;
J. Hogan, University of Pennsylvania; L.B. Holzman, University
of Pennsylvania*; J. Ashley Jefferson, University of Washing-
ton; K. Jhaveri, North Shore University Hospital; D.B. John-
stone, Temple University; F. Kaskel, Monteﬁore Medical
Center; A. Kogan, CHOP; J. Kopp, NIDDK Intramural Research
Program; R. Lafayette, Stanford; K.V. Lemley, Children’s
Hospital of Los Angeles; L. Malaga-Dieguez, NYU; Kevin
Meyers, Children’s Hospital of Pennsylvania; A. Neu, Johns
Hopkins; M.M. O’Shaughnessy, Stanford; J.F. O’Toole, Case
Western/Cleveland Clinic; R. Parekh, University Health;
Network, Hospital for Sick Children; H. Reich, University
Health Network, University of Toronto, Toronto, CAN; K. Reidy,
Monteﬁore Medical Center; H. Rondon, UPMC; K.K. Samban-
dam, UT Southwestern; J.R. Sedor, Case Western/Cleveland
Clinic; D.T. Selewski, University of Michigan; C.B. Sethna,
Cohen Children’s Medical Center-North Shore Long Island
Jewish (LIJ) Health System; J. Schelling, Case Western Reserve
University; J.C. Sperati, Johns Hopkins; A. Swiatecka-Urban,
Children’s Hospital of Pittsburgh; H. Trachtman, New York
University; K.R. Tuttle, Spokane Providence Medical Center; J.
Weisstuch, New York University; O. Zhdanova, New York
University.
Data Coordinating Center (DCC): Laura Barisoni, University
of Miami; B. Gillespie*, University of Michigan; D.S. Gipson*,
University of Michigan; M. Helmuth, Arbor Research
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Collaborative for Health; M. Kretzler*, University of Michigan;
S. Mansﬁeld, Arbor Research Collaborative for Health; L.
Mariani, University of Michigan; C.C. Nast, Cedars-Sinai
Medical Center; B.M. Robinson*, Arbor Research Collabora-
tive for Health; M. Wladkowski, Arbor Research Collaborative
for Health; J. Zee, Arbor Research Collaborative for Health.
Steering Committee Chair: Lisa M. Guay-Woodford, Chil-
dren’s National Health System.
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recruitment is supported by NephCure Kidney International.
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